Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053937 · ClinicalTrials.gov registry record · Phase 1
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00053937: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00053937 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00053937, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Pirfenidone may slow the growth or prevent further development of plexiform neurofibromas. PURPOSE: Phase I trial to study the effectiveness of pirfenidone in treating young patients who have neurofibromatosis type 1 and plexiform neurofibroma.
Interventions
- DRUG pirfenidone
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-12 |
| Phase | Phase 1 |
What the finished NCT00053937 record still lists
NCT00053937 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which pirfenidone is the first listed.
NCT00053937 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00053937 about?
NCT00053937 is a clinical study titled "Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Pirfenidone may slow the growth or prevent further development of plexiform neurofibromas. PURPOSE: Phase I trial to study the effectiveness of pirfenidone in treating young pat...
What is the current status of trial NCT00053937?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-12.
What interventions are being tested in trial NCT00053937?
The interventions under investigation include: pirfenidone (DRUG).
Who is sponsoring clinical trial NCT00053937?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia